Abiopharma

🔍 Jung Cassie (Executive)

Company: Aquestive Therapeutics, Inc. (AQST)

Report Date: 2025-09-04

Detailed Transactions and Holdings:

• Acquired 25,000 shares of Common Stock at $3.15 per share (Direct)
  Date: 2025-09-04 | Code: M | equity_swap_involved: false | shares_owned_after: 320,526.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 25,000 shares of Common Stock at $0.7063 per share (Direct)
  Date: 2025-09-04 | Code: M | equity_swap_involved: false | shares_owned_after: 345,526.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 62,180 shares of Common Stock at $5.0 per share (Direct)
  Date: 2025-09-04 | Code: S | equity_swap_involved: false | shares_owned_after: 283,346.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-09-04 | Code: H | nature_of_ownership: by spouse | shares_owned_after: 2,000.00
• Sold 25,000 shares of Non-Qualified Stock Option (right to buy) at $3.15 per share (Derivative)
  Date: 2025-09-04 | Code: M | Expires: 2029-08-09 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 25,000 shares of Non-Qualified Stock Option (right to buy) at $0.7063 per share (Derivative)
  Date: 2025-09-04 | Code: M | Expires: 2032-08-05 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F4

Footnotes:

• F1: This is a scheduled exercise from 10b5-1 trading plan. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected.
• F2: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4.
• F3: This option was granted on August 9, 2019 and is fully vested.
• F4: This option was granted on August 5, 2022 and is fully vested.